Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.96 +0.02 (+0.14%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study
Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral... 
Via Benzinga
The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With... 
Via Benzinga
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug... 
Via Benzinga
Takeda Celebrates World Quality Week
SOURCE: Takeda 
Via 3BL Media
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to... 
Via FinancialNewsMedia
Exposures Product Safety
Novavax Files For Approval Of Its COVID-19 Vaccine In Japan
Novavax Inc (NASDAQ: NVAX) has submitted a marketing application in Japan seeking approval for its COVID-19 vaccine by its partner Takeda Pharmaceutical Co Ltd... 
Via Benzinga
3 Stocks That Can Make You Rich in Just a Few Years
Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed. 
Via InvestorPlace
Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
Sanofi SA (NASDAQ: SNY) and Johnson & Johnson (NYSE: JNJ) posted new data from their myeloma therapies, Sarclisa and Darzalex, respectively. Data were shared at... 
Via Benzinga
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
From Takeda Pharmaceutical Company Limited
Via Business Wire
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
Exposures COVID-19
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
Happy December
Inflation levels this year will almost certainly lower growth in 2022 because of inflation this year in everything from house prices....to stock prices. 
Via Talk Markets
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, & More
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant helped mitigate the losses notched earlier in the holiday-shortened week. 
Via Talk Markets
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Takeda's Maribavir Scores FDA Approval For Post-Transplant CMV Infection
The FDA has approved Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Livtencity (maribavir) for a common type of viral infection occurring in patients after... 
Via Benzinga
Exposures Product Safety
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Synlogic Presents Positive Phase 2 Data For Synthetic Biologic Treatment In... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week
Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the... 
Via Benzinga
Exposures Product Safety
Monday Market Coverage
Gold is up today on inflation fears. 
Via Talk Markets
Takeda, Shattuck Labs Terminate Immuno-Oncology Pact
Shattuck Labs Inc (NASDAQ: STTK) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) mutually agreed to terminate the Collaboration Agreement for SL-279252 and SL-115154... 
Via Benzinga
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For November PDUFA Dates
The loaded Prescription Drug User Fee Act (PDUFA) calendar for October produced mixed outcomes. PDUFA dates are key binary events for biotech stocks that can move the needle in a... 
Via Benzinga
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
From Takeda Pharmaceutical Company Limited
Via Business Wire
No Negative Reaction
Today the impact of the Delta variant hit US GDP which was only 2% annualized, vs estimates of 2.6%, based on Q3 data which came out today. 
Via Talk Markets
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.